Previous studies has shown that NF-κB activation was inhibited when bortezomib was added, suggesting that bortezomib can sensitize MM cells to alkylating agents by inhibiting NF-κB activation [36]. This evidence concerns the gene NFKB1 and Miyoshi myopathy.